Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The primary aim of this trial is to estimate the duration of hepatic progression-free
survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial
Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary
hypothesis is that chemoembolization will be nearly twice as durable as bland embolization;
thatis, the hazard ratio for HPFS will be 1.76 or better.
Phase:
Phase 3
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania